# Bioequivalence Study to Compare Selexipag 400 Microgram Film Coated Tablets Versus Uptravi® (Selexipag) 400 Microgram Film Coated Tablets

> **NCT07694128** · PHASE1 · COMPLETED · sponsor: **Humanis Saglık Anonim Sirketi** · enrollment: 30 (actual)

## Conditions studied

- Arterial Hypertension (PAH)

## Interventions

- **DRUG:** Selexipag Film Coated Tablets (T1)
- **DRUG:** Selexipag Film Coated Tablets (T2)
- **DRUG:** Uptravi® (selexipag) film coated tablets

## Key facts

- **NCT ID:** NCT07694128
- **Lead sponsor:** Humanis Saglık Anonim Sirketi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2026-04-08
- **Primary completion:** 2026-06-16
- **Final completion:** 2026-06-22
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2026-07-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07694128

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07694128, "Bioequivalence Study to Compare Selexipag 400 Microgram Film Coated Tablets Versus Uptravi® (Selexipag) 400 Microgram Film Coated Tablets". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07694128. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*